{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-025159","form_type":"8-K","ticker":"PTIX","cik":"0001022899","company_name":"Protagenic Therapeutics, Inc.new","filed_at":"2025-11-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.570226+00:00","generated_at":"2026-05-16T16:21:50.435456+00:00","sec_items":["3.01","7.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Protagenic Therapeutics receives Nasdaq delisting notice for equity and filing non-compliance","bullets":["Stockholders' equity fell below $2.5M minimum per Listing Rule 5550(b)(1) as of June 30, 2025.","Company also cited for delayed Form 10-Q for quarter ended September 30, 2025 (Rule 5250(c)(1)).","Will request hearing before Nasdaq Hearings Panel; automatic 15-day stay of suspension granted.","Common stock and warrants will continue trading on Nasdaq during automatic stay and any extended stay.","Company expects to file the overdue 10-Q imminently but no assurance Panel will grant relief."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-025159","json":"https://secwatch.observer/filing/0001493152-25-025159.json","markdown":"https://secwatch.observer/filing/0001493152-25-025159.md","text":"https://secwatch.observer/filing/0001493152-25-025159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022899/000149315225025159/0001493152-25-025159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022899/000149315225025159/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T16:21:50.435456+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d1d23a02195a5eb1d7978ab4ef5bfe4c274cf45","claim":"Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"November 20, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter (the “Notice” ) from the Nasdaq Listing Qualifications Staff (the “Staff” ) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) (minimum stockholders’ equity of $2,500,000) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). As reported in the Company’s Transition Report on Form 10-QT for the period ended June 30, 2025, the Company’s stockholders’ equity no longer satisfies the minimum requirement of Rule 5550(b)(1). The Staff also cited the Compa","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000149315225025159/0001493152-25-025159-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"late filing"},{"label":"Rules","value":"5250(c)(1)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"aeca02182fec6f737662a18971b5c228de4eb619","claim":"Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"November 20, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter (the “Notice” ) from the Nasdaq Listing Qualifications Staff (the “Staff” ) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) (minimum stockholders’ equity of $2,500,000) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). As reported in the Company’s Transition Report on Form 10-QT for the period ended June 30, 2025, the Company’s stockholders’ equity no longer satisfies the minimum requirement of Rule 5550(b)(1). The Staff also cited the Compa","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000149315225025159/0001493152-25-025159-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}